

[Document Name]Written Amendment
[Reference Number]PF13046
[Date of submission]Heisei 31(2019) January 9
[Recipient] Commissioner of the Patent Office
[Indication of case]
[Application number]Japanese Patent Application No. 2017-93750
[Person who submits written amendment]
[Identification Number]513084469
[Name]ModernaTX, Inc.
[Representative]
[Identification Number]100105957
[Patent attorney]
[Name]ONDA, Makoto
[Dispatch number] 291869
[Amendment 1]
[Document name for target of amendment]Patent Claims
[Item name for target of amendment]Claim 1
[Amendment type]Change
[Content of amendment]

[Claim 1]

A composition comprising a plurality of lipid nanoparticles, wherein said plurality of lipid nanoparticles has an average particle size of 80nm-150nm .

(a) an open reading frame encoding a oncology related protein comprising a nucleotide comprising a nucleoside selected from a modified uridine, a cytidine, an adenosine and a guanosine ;

(b) a 5 ' - UTR comprising a Kozak sequence and (c) at least one 5 ' cap structure ;

(d) a 3 ' - UTR comprising at least one target sequence of miR - 122 to down-regulate or inhibit expression in cells expressing miR - 122 ;

A composition comprising a polynucleotide comprising a 3 ' tail sequence of a plurality of linked nucleotides.

[Amendment 2]

[Document name for target of amendment]Patent Claims
[Item name for target of amendment]Claim 6
[Amendment type]Change
[Content of amendment]

[Claim 6]

A composition according to any one of claims 1 to 5, wherein the open reading frame consists of a nucleotide comprising a 1 - methyl-pseudouridine, cytidine, adenosine and guanosine or a nucleoside selected from 5-methoxy-uridine , cytidine, adenosine and guanosine.

[Amendment 3]

[Document name for target of amendment]Patent Claims

[Item name for target of amendment]Claim 9
[Amendment type]Change
[Content of amendment]

[Claim 9]

The composition of any one of claims 1 to 8, wherein said plurality of lipid nanoparticles have an average PDI of 0.02 to 0.2 and an average lipid : polynucleotide ratio (weight / weight) of 10 to 20.

[Amendment 4]

[Document name for target of amendment]Patent Claims
[Item name for target of amendment]10.
[Amendment type]Change
[Content of amendment]

[Claim 10]

A composition according to any one of claims 1 to 9, wherein the 3 ' tail sequence of said plurality of linked nucleotides is selected from a polyA tail of about 150 to 165 nucleotides and a polyA-G 4 triplet of nucleotides.